The interactions between ligands containing the recognition sequence arginine-glycine-aspartic acid (RGD) and integrin receptors are important in many cell-cell and cell-protein interactions. The platelet contains five integrin receptors and they contribute significantly t o platelet adhesion and aggregation. To investigate the RGD binding domains on platelet integrins, we immobilized a series of RGD peptides containing variable numbers of glycine residues [(G),-RGDF] on polyacrylonitrile beads and evaluated the ability of the beads t o interact with platelets. With native platelets, virtually no interaction occurred with G,-RGDF beads, but the interactions increased as the number of glycine residues increased, plateauing with the G,-RGDF and G,,-RGDF beads. ADP
pretreatment enhanced the interactions with all of the beads, whereas prostaglandin E, pretreatment eliminated the interactions with the shortest peptide beads, but only partially inhibited interactions with the longer peptide beads. Monoclonal antibodies t o glycoprotein (GP) Ilb/llla were most ONSIDERABLE evidence indicates that the interac-C tions between glycoprotein (GP) ligands containing the recognition sequence arginine-glycine-aspartic acid (RGD) and receptors in the integrin superfamily that contain RGD binding sites are of major biologic significance in many cell-cell and cell-protein intera~ti0ns.I.~ The molecular details of the RGD binding sites on these receptors have remained elusive, but recent peptide crosslinking studies6-8 and inferences derived from a patient with an abnormal receptor' have identified potential RGD binding regions in the proteins.
The human platelet contains five different integrin receptors (Table l)3,5.1"-'8 and there is evidence that three of them, GPIIb/IIIa (allb/IIIa),32'0 the vitronectin receptor (VnR; a,,p3),331y and the fibronectin receptor (VLA-5; c&),'.~" bind their ligands via RGD-dependent mechanisms. The data for the other two integrins, the collagen receptor (VLA-2; a 2 1 p )12,13. 21, 22 and the laminin receptor (VLA-6; a6ysP1),18 are less convincing for RGD-mediated binding, but the data are inadequate to exclude this possibility, especially because their ligands do, in fact, contain RGD sequence^.^^-^ The platelet surface copy numbers for the different integrin receptors are remarkably disparate, with the GPIIb/IIIa receptor so dominant as to be represented by an order of magnitude more receptors than the sum of all of the other integrins. 1OJ3.27.28 Assuming that the receptors are evenly spaced and that the platelet surface area is 22.2 p2,2y it is possible to calculate the mean distance between receptors;
for GPIIb/IIIa, this is only 214 A.
To gain additional information o n the RGD binding domains of the platelet integrins, we have immobilized a series of RGD peptides containing variable numbers of glycine residues as spacers [(G),-RGDF] on polyacrylonitrile beads via their amino-terminal glycine residues and evaluated the ability of these beads to interact with platelets. The differential platelet agglutinating effects of these beads as a function of the number of glycine residues permitted us to explore the RGD binding site(s) under effective in inhibiting the interactions, but antibodies t o GPllb/llla with similar inhibitory effects on fibrinogen binding varied dramatically in their ability t o inhibit the interaction between platelets and immobilized RGD peptides. Our data indicate that the majority of RGD binding sites on GPllb/llla can be reached by peptides that extend out -11 t o 32 A from the surface of the bead, and these results are in accord with the dimensions of integrin receptors deduced from electron microscopy. Activation of GPllbl llla facilitates the interactions, but platelet inhibition fails t o eliminate the interactions with the longer peptide beads, suggesting that access t o the RGD binding site on at least a fraction of the GPllb/llla receptors is always possible for preferred ligands. Finally, we found that the G,-RGDF peptide beads were uniquely sensitive t o the activation state of the GPllb/llla receptor. o 1992 by The American Society of Hematology.
basal conditions and in the presence of platelet agonists and inhibitors. In addition, we were able to analyze a series of monoclonal antibodies (MoAbs) directed at the different integrin receptors for their ability to inhibit the interactions. tThe molar concentration equivalent is the molar concentration of a solution in which the molecules are the number of angstroms apart that are specified in the mean distance between molecules. The molar concentration equivalent is provided to assist in conceptualizing the density of peptides and proteins immobilized on the beads, but this is not meant to imply an equivalence between fluid-phase and immobilized peptides or proteins for the purpose of kinetic measurements.
*Assumes a platelet surface area of 22.2 p' and equal spacing between receptors.
greatest platelet inhibitory potency of the small RGD-containing peptides;" an observation that we confirmed in our own studies. The peptides (G),-RGDF were synthesized on two different occasions on a solid-phase synthesizer (Applied Biosystems, Foster City, CA; Model 430A) using t-Boc chemistry; a 4-methylbenzhydrylamine (4-MBHA) resin was used so that the peptides contained carboxy-terminal amides rather than free carboxyl groups after cleavage. Benzyl-ester and tosyl side chain protection groups were used, respectively, for aspartic acid and arginine. Double couplings were used for arginine, phenylalanine, and glycine residues beyond n = 4 or 5. The peptides were cleaved from the resin with H F in the presence of anisol and dimethylsulfide (1Ol:l by volume), washed with ethyl ether, extracted with HAC, and lyophilized. Peptide homogeneity, assessed by high performance liquid chromatography (HPLC) using a C, reverse-phase column (Aquapore RP-300;
Applied Biosystems, 300 8, pore size, 7 p spherical silica, 4.6 X 220 mm) was 72% 2 5% (mean 2 SEM) in one synthesis and 80% ? 3% in a second. Because GI,-RGDF exhibited the poorest homogeneity as judged by HPLC (56%), it was purified to greater than 95% homogeneity with preparative reverse-phase HPLC. The functional activities of the crude and purified GI,-RGDF peptides in the bead agglutination assay were the same. A fibrinogen y-chain dodecapeptide (amino acids 400 to 411) containing an added amino-terminal tyrosine (Y-HHLGGAKQAGDV) was a gift from Dr Ellinor Peerschke (State University of New York at Stony Brook, NY). The snake venom peptide trigramin, which contains an RGD sequence and inhibits fibrinogen binding to GPIIb/IIIa,)' was a gift of Dr Stephan Niewiarowski (Temple University, Philadelphia, PA).
Fast atom bombardment mass spectrometry was performed on peptides prepared in the second synthesis by collecting the HPLC elution peaks, drying the samples under vacuum (Speed Vac Concentrator; Savant Instruments Inc, Farmingdale, NY), and redissolving them either in methanol (G,,-RGDF) or 25% HC1 (G,,,-RGDF). For the G,.,,-RGDF peptides, the mass spectrometry probe was precoated with 1 pL of 50% glycerine/50% thioglycerine matrix and then 1 p,L of the peptide solution was added; for the G,,,,-RGDF peptides, the probe was precoated with 1 pL of thioglycerine matrix and then 1 p L of the peptide solution was added. The fast atom bombardment mass spectra were generated on a Kratos MS890/DS90 mass spectrometry system (Ramsey, NJ). A saddle field ion source (Ion Tech, Middlesex, UK) was used as a source of fast xenon atoms; it produced 1 mA of ion current when operated at 7 kV. The mass spectrometer was operated at 6 to 8 kV and the mass range was calibrated with cesium iodide in the positive ion mode using a 10 secldecade scan speed. After adjusting for the 1 amu added to the molecule by protonation, the observed molecular weights of all peptides prepared in the second synthesis (GI.,,-RGDF) matched precisely the predicted molecular weights. To verify the identity of the peptides prepared in the first synthesis, 1:l mixtures of the corresponding peptides in the first and second syntheses were analyzed by HPLC and all of them showed only a single peak.
For studies to assess the effect of RGD-containing peptides on
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From the binding of radiolabeled MoAbs to platelets, the peptide RGDS was obtained from Peninsula Laboratories (Belmont, CA) or synthesized as described above. A longer peptide that is a composite of the y-chain decapeptide (402 to 411) and one of the polyarginine RGDV peptides described by Ruggeri et a13' [LGGAKQAGDV(R),RGDV] was also tested. This peptide was synthesized as above; HPLC showed a single major peak containing more than 67% of the absorbance.
The BIOGRAPH molecular modeling computer program (Bio Design, Inc, Pasadena, CA; version 1.34) was used to determine the peptide lengths. Calculations were made for the peptides in both the extended form and in the a-helical conformation so as to span these two extreme possibilities. We do not know the exact conformation of the peptides in solution, but we suspect that the glycines attached to the RGDF assume a multitude of random conformations because of the rotational freedom of glycine residues. It is possible, however, that immobilization of the peptides on the beads at high density limits this conformational freedom.
Fibrinogen bead assay and functional assessment of G,-RGDF peptides. The fibrinogen-bead agglutination assay was performed as previously described." Briefly, fibrinogen (lot number PR2548; Cutter Laboratories, Berkeley, CA) purified according to the method of Mose~son'~ was coupled to 1 to 3 p polyacrylonitrile beads containing N-hydroxysuccinimide groups at a ratio of 3 mg fibrinogedl mL bead slurry (containing 67 mg beads) (Matrex 102; Amicon, Danvers, MA). After coupling was completed, the beads were washed extensively with 0.15 mol/L NaCI, 10 mmol/L TrislHCI, pH 7.4, containing 0.05% sodium azide (TSA), resuspended in TSA, and kept at 4°C. To perform the assay, 35 pL of citrated PRP (3 X lO"/L) was incubated with 35 pL of peptide in TSA in a round-bottom 96-well microtiter plate for at least 10 minutes at 22°C. Then, 5 p L of beads containing -0.4 kg of bound fibrinogen ( -5 x lo5 molecules per bead) was added and the plate was rotated at 260 rpm. The degree of agglutination was graded visually on a scale between 0% and 100% as a function of time. Antibody 10E5, which binds to GPIIb/IIIa and blocks fibrinogen binding," produces complete inhibition of bead agglutination in this assay when used at 10 to 20 pg/mL, and so a sample containing 10E5 instead of peptide was included in each assay as a positive control. A negative control consisting of TSA buffer instead of peptide was also included in each assay; this control consistently reached maximal agglutination (100%) after 4 minutes and so the inhibitory effects of the peptides GI,-RGDF in solution were also assessed after 4 minutes. The longer peptides, GI, ,,-RGDF, were poorly soluble under these conditions and so could not be tested in this manner (see below).
One milliliter of the polyacrylonitrile beads (67 mg) (Matrex 102, Lot nos. JC 1236 and 1239) in dry dioxane was centrifuged at 10,00$ for 1 minute at 22"C, the supernatant dioxane removed, and the beads rapidly washed twice with 0.05 mol/L Na acetate, pH 5.5. The pelleted beads were then resuspended in 1 mL of a 4.05 mmol/L solution of peptides GI-, G3-, G5-, G7-, or Cy-RGDF in 0.05 mol/L Na acetate buffer, pH 6.5, and allowed to rock overnight at 4°C. Any remaining reactive N-hydroxysuccinimide groups were blocked by adding 0.1 vol of 1 mol/L glycine ethyl ester, pH 8, for 30 minutes at 22°C. The beads were then washed extensively in TSA, pH 7.4, resuspended in a volume of 1.5 mL of TSA, and stored at 4°C. The GI,-, GI,-, CIS-, GI,-, and GI,-RGDF peptides were only partially soluble in the acetate buffer, but they were fully soluble in 0.1% trifluoroacetic acid (TFA), pH 2.5, at 22°C or 37°C. The GI,-, GI,-, GI,-, GI,-, and GI,-RGDF peptides, therefore, were coupled to the beads in 0.1% TFA, pH 2.5, for 72 hours. For comparison purposes, the GI-, G3-, G5-, G7-, and Cy-RGDF peptides were also coupled to beads under these circumstances and these beads were Covalent coupling of peptides to beads. similar in coupling efficiency and platelet agglutinating activity to those coupled in the acetate buffer (see below). BSA (essentially globulin free; Sigma, St Louis, MO) at 30 Kmol/L was coupled to 1 mL of the beads as a control. In another series of experiments to assess the impact of decreasing the density of peptides on the beads, the G,-RGDF and Cy-RGDF peptides were diluted to concentrations between 0.4 pmol/L and 4.05 mmol/L before coupling.
Coupling efficiency was assessed by HPLC by comparison of the areas under the peptide peaks in the precoupling and postcoupling samples, and the results are presented in Table 1 . For the standard method using 4.05 mmol/L peptide, the GI-, G3-, G5-, G7-, and Cy-RGDF peptides at pH 6.5 and the GI,-, GI,-, GI,-, GI,-, and G,,-RGDF peptides at pH 2.5 were coupled at -74% and -91% efficiency, respectively. Assuming an average coupling efficiency of 80% for these peptides, then -1.9 x 10l8 peptide molecules were bound to each 67 mg of beads [(4.05 pmol/mL) (6.02 x loi7 molecules/ kmol) (0.81); this number of molecules represents -40% of the N-hydroxysuccinimide groups on the beads, indicating the high efficiency of coupling. Because the estimated surface area of the beads is 6 mZ/g, the peptides are -4.6 8, apart on the beads = 0.63 m or 6.3 x 10' 8,; SL" 1.9 x 10l8 molecules = 1.38 x lo9 molecules; (6.3 x lo9 A)/ (1.38 X 10' molecules) = 4.6 8, per molecule] ( Table 1) . Although one cannot equate surface densities and fluid-phase concentrations for the purpose of kinetic calculations, one way to conceptualize the high density of the immobilized peptides is to translate the results into an "equivalent molar concentration"; thus, when molecules are 4.6 8, apart in fluid phase, the solution is 17 moi/L.
For comparison, the mean distances between fluid-phase peptides at various concentrations are also given, as are comparable values for fibrinogen molecules on beads, fibrinogen molecules in plasma, albumin molecules on beads, and albumin molecules in plasma. Table 2 lists the antibodies, their specificities, and the concentrations used. They have all been characterized previously: antibodies 10E5,'4 7E3,96 6D1:7 and 6F1I3 are from our laboratory; antibody A2A93R was a gift of Dr Joel Bennett (University of Pennsylvania, Philadelphia); antibody PAC-l', was a gift of Dr Sanford Shattil (University of Pennsylvania); antibody LM 60940 was a gift of Dr David Cheresh (Scripps Research Institute, La Jolla, CA); antibody GoH3"was a gift of Dr A. Sonnenburg of the Netherlands Red Cross; and antibody M0Ab16~' was a gift of Dr Kenneth Yamada (National Institutes of Health, Bethesda, MD). The platelets were incubated with the antibody concentrations indicated for 30 to 60 minutes before the addition of the beads. In the case of PAC-1, which binds only to activated platelets," the platelets were activated with ADP (6.7 pmol/L final concentration) without stirring for 5 minutes before adding the antibody.
To 70 p L of PRP or GFP at a count of 3 x 10" plateletdl in a 96-well round-bottom polystyrene microtiter plate, 5 p L of a well mixed bead suspension (0.22 mg beads) was added and the plate was rotated at 260 rpm (Orbit shaker; Lab Line Instruments, Melrose Park, IL) for various times between 0 and 30 minutes (0.5, 1,2,4,6,8, 10, 12, 15,20,25, and 30 minutes). At the indicated times the wells were observed from the bottom with the aid of a magnifying mirror apparatus (Cooke Microtiter System, Dynatech Laboratories, Inc, Alexandria, VA) and the degree of the bead-agglutination was rated visually from 0% (no visible agglutination, indistinguishable from the control, albumin-coated beads) to 100% (full agglutination) ( Fig 1A) . Platelet counts in the supernatant plasma or buffer were measured by removing 5 JLL from the supernatant after allowing the bead agglutinates to settle for 3 minutes. The platelet counts decreased during the agglutination, indicating that increasing numbers of platelets were incorporated into the agglutinates ( MoAbs.
Agglutination assay with peptide-coated beads.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 120 BEER, SPRINGER, AND COLLER 1). In some experiments, platelets were activated with 6.7 kmol/L ADP 30 seconds before the addition of the beads; in other experiments, the platelets were preincubated with 0.14 pmol/L prostaglandin E, (PGE,; Sigma) for 30 minutes. Control experiments indicated that there was no agglutination at all in the presence of EDTA (10 mmol/L). There was only a minimal increase in the supernatant lactate dehydrogenase level during the agglutination, indicating that the platelet-bead interaction did not produce significant platelet lysis. Citrated PRP (3 X lo"/ L) was incubated with ''C-5-serotonin (10 pCi/mL stock solution, 20 to 25 nCi/mL final concentration; New England Nuclear, Boston, MA) for 30 minutes at 22°C with gentle stirring ( -100 rpm) using a teflon-coated stir bar. To maintain the PRP pH constant at -7.60, the PRP was overlayed with 5% CO,, 95% air just before the incubation began. Serotonin uptake was terminated by adding 5 kmol/L imipramine (Sigma) and stirring was continued for another 5 minutes. Total uptake under these conditions was 70% to 80% of the added serotonin. The agglutination assay was performed in quadruplicate in the same way as described above except that after 8 minutes of shaking, 70 WL of cold 2% paraformaldehyde in phosphate-buffered saline (PBS), pH 7.4 was added to the wells and the microtiter plate was centrifuged at 1, OOOg for 5 minutes at 22°C. The top 50 pL of the supernatant (total volume in each well was 145 kL) was added to scintillation fluid and counted in a scintillation spectrometer. In some experiments, the PRP was preincubated with acetylsalicylic acid (50 pmol/L) or PGE, (0.14 p,mol/L) during the serotonin uptake.
To assess the effect of RGD-containing peptides on the initial rate of binding of 7E3 and 10E5, studies were conducted with IzI-7E3 and '"1-10E5 essentially as described before.36 The RGDS or LGGAKQAGDV(R),RGDV peptide was incubated at 22°C with citrated PRP (-3.0 x 10"/mL) for 1 to 5 minutes at various concentrations and then nonsaturating concentrations of the antibodies (1.5 to 2.5 kg/mL) were added for 1 to 2 minutes. The platelet-bound antibody was separated from the free antibody by centrifugation of the PRP through 20% sucrose and both the platelet pellet and the supernatant were counted. Results were expressed as either an increase or decrease in antibody binding as compared with a buffer control.
Release of "C-serotonin from platelets.
Effect of RGDpeptides on 7E3 and IOE5 binding.

RESULTS
Effects of soluble G,,-RGDF peptides on the fibrinogen bead assay.
The ability of the soluble G,,-RGDF peptides to inhibit platelet-fibrinogen interactions was tested with the fibrinogen bead assay. There was a distinct decrease in potency with increasing numbers of glycine residues, with the RGDF peptide approximately 10-fold more potent than the G,-RGDF peptide. The mean concentrations required to prevent complete agglutination in two separate experiments were 16 and 32 p.mol/L for G,-RGDF, 63 and 113 wmol/L for G,-RGDF, and 227 and 253 pmol/L for G,-RGDF. The decreased potency of the longer peptides is unlikely to be accounted for solely on the basis of decreased diffusion coefficients because the molecular weight of the G,-RGDF peptide (786) is less than twice that of the RGDF peptide (435).
As one of us previously the albumin-coated beads were not agglutinated by the platelets, even when ADP was added. This finding indicates that the beads are not nonspecifically incorporated into the platelet aggregates that form when ADP is added.
The data in Figs 1 and 2 show the extent of agglutination of (G),-RGDF beads by PRP as a function of time and the number of glycine residues. Both the total plateletagglutinating activity and the speed of agglutination increased dramatically as the number of glycine residues increased from 1 to 13 and then the activity decreased as the number of glycines increased further to 19. The G,-RGDF beads gave values between those produced by the G,-RGDF and G,-RGDF beads, and the GI,-RGDF and GI,-RGDF beads gave values that were similar to those of the G,,-RGDF beads. Thus, even though the shorter RGDF peptides were more potent than the G,-RGDF peptide when tested in fluid phase in inhibiting the fibrinogen bead assay, the immobilized G,-RGDF peptide was much more potent in agglutinating platelets than the Peptide bead agglutination assay. (G),-RGDF bead agglutination in PRP. The experiment was conducted as above using G,-RGDF, G,-RGDF, and G,-RGDF beads. The reaction was stopped at the time points indicated on the left and the microtiter plate was photographed. The grading of the extent of agglutination is indicated on the right of each well. Note the minimal agglutination with the G,-RGDF beads, the modest agglutination with the G,-RGDF beads, and the extensive agglutination of the G,-RGDF beads over the first 8 minutes. The addition of ADP to the platelets before the (G)"-RGDF beads increased both the speed and extent of agglutination with all of the different beads ( Fig 3A) . The G,-RGDF beads showed the greatest increase in total extent of agglutination with ADP stimulation, going from 44% 2 6% (n = 17) to 96% 2 4% (n = 7) at 30 minutes. Thus, preactivation of the platelets with ADP appears to 9921 1 G 3
SUPE
PLT Count (xlOb/mI 1
G9
increase the affinity of the RGD-binding sites and/or reduce their distance from the platelet surface. Preincubation of the PRP with PGE, significantly diminished the ability of the PRP to agglutinate the (G),-RGDF beads. The agglutination of the GI-RGDF and G,-RGDF beads was completely abolished, but agglutination with the longer beads was less affected; in fact, the G,-RGDF beads underwent 75% 2 16% (n = 7) agglutination at 30 minutes and the GI,-RGDF beads underwent 88% 2 13% (n = 4) at the same time point. Thus, the inhibition of platelet activation by PGE, was not able to prevent significant interactions between platelets and the longer ( beads. The beads coated with the G,-RGDF peptide showed the most marked differences in platelet interaction as a function of platelet activation; PGE, totally inhibited the interactions, whereas ADP dramatically increased both the speed and extent of agglutination ( Fig 3B) . Thus, the G,-RGDF peptide appears to have a critical length or flexibility for reporting on the state of activation of the RGD receptor site(s). Platelets fixed with formaldehyde3' could not support bead agglutination even with the G,-RGDF beads, indicating that platelets are not playing a purely passive role in the process. Decreasing the number of peptides on the bead surface decreased the agglutination reaction (Fig 4) , but full agglutination could eventually be achieved even when the peptide number was decreased nearly 10-fold. Some agglutination of PRP occurred even when the peptide number was reduced approximately 100-fold. With ADP preactivation, all of the bead preparations showed enhanced agglutination and full agglutination was even achieved with the beads containing approximately 100-fold fewer peptides. Based on the density calculations (Table l) , these data indicate that a peptide-peptide distance on the beads 5 13 8, is required for full agglutination of nonactivated platelets, whereas a peptide-peptide distance 1 4 1 8, is adequate for full agglutination of ADP-activated platelets.
The inhibitory effects of free RGDF and y-chain pep-tides on the bead agglutination were also investigated. High RGDF concentrations were required to inhibit the agglutination of the beads containing the longer peptides ( Table  2 ) and lower concentrations were required with the shorter peptide beads. For example, 41 pmol/L RGDF abolished agglutination with G,-RGDF beads, whereas 400 ymol/L was required to abolish agglutination with G,-RGDF beads, and 3 to 4 mmol/L RGDF was needed to abolish agglutination with beads containing seven or more glycine residues. Lower concentrations of RGD peptides produced incomplete inhibition that was most notable during the early phase of platelet agglutination. The fibrinogen y-chain dodecapeptide derivative also inhibited agglutination of the (G),-RGDF beads; on a molar basis, the potency of the inhibition of the y-chain peptide was slightly less than that of the RGDF peptide ( Table 2 ). The interaction of the platelets in PRP with the longer immobilized peptides resulted in the release of serotonin, and the extent of release correlated with the extent of agglutination. For G,-RGDF beads serotonin release was 1% of maximal, for G,-RGDF beads it was 9%, and for G,-RGDF beads it was 19%. Preincubation of the platelets with acetylsalicylic acid (50 ymol/L) did not change this pattern. PGE,, however, abolished release for the 8 minutes of agglutination with all the beads, but the agglutination response with the longer beads still reached 50%. Thus, it can be inferred that the release reaction is not a prerequisite for agglutination, but it may amplify and accelerate the response.
Gel-filtered platelets showed a pattern of interaction with the beads that was similar to that observed with PRP in that the agglutination was dependent on the peptide length and was enhanced by activating the platelets with ADP (data not shown). These data indicate that interaction of the beads with plasma proteins is not required for agglutination. However, there were some minor differences in agglutination with GFP compared with PRP. Thus, with the beads containing the shorter peptides, the agglutination by GFP was slower and less extensive than with PRP. In contrast, with the beads containing the longer peptides, the agglutination by GFP was somewhat brisker than that produced by PRP, although the ultimate extent of agglutination was maximal with both platelet preparations. The effects of gel-filtration on platelet functions, the presence of plasma proteins, and/or the differences in pH (PRP pH -7.70 and GFP pH 7.40) probably account for these minor differences.
10E5, A 2 b , 7E3, and PAC-1, which interact with GPIIb/IIIa and inhibit fibrinogen binding to platelets, all inhibited the interaction of platelets in PRP with GI-RGDF, G,-RGDF,
The interaction of GFP with RGDF beads.
Effect of MoAbs on RGDF bead agglutination.
and G,-RGDF beads by greater than 90%, even with ADP activation. However, with the longer beads differences in the antibodies' inhibitory potency became apparent. As shown in Fig 5 with the G,-RGDF beads, 10E5 markedly delayed the agglutination response, but by 30 minutes it reached -60% of the control value. Because 10E5 blocks platelet aggregation, this shows that platelet aggregation is not required for agglutination to occur. Increasing the 10E5 concentration threefold (to 60 Fg/mL) did not change this pattern. A2G, produced greater, but still incomplete, inhibition with the agglutination reaching only 38% by 30 minutes. 7E3 produced the most extensive inhibition, with no agglutination detectable at 30 minutes. When the assay was performed with platelets that were stimulated with ADP, 10E5 and A2& were somewhat less inhibitory, especially at the earlier time points, but the differences were still dramatic compared with the control (data not shown). 7E3 was still able to produce complete inhibition under these circumstances. With GI,-, GI,-, and GI,-RGDF beads and ADP-activated PRP, however, even 7E3 could not completely inhibit agglutination, with the values reaching 13% to 25% after 30 minutes (data not shown).
One possible explanation for the inhibitory potency of 7E3 is that it reacts with a$, VnR in addition to GPIIbl IIIa.28.42 To assess this, we studied the effect of antibody LM 609, which reacts with a$, but not GPIIb/IIIa, and can Table 1 for coupling efficiencies and for maximal mean distances between peptides). The agglutination of the beads by PRP was then tested as indicated For personal use only. on October 3, 2017. by guest www.bloodjournal.org From block a$, function.z8.40 Antibody 7E3 also can inhibit a$, function28342 and preincubation of platelets with 7E3 decreases the binding of '"I-LM 609 (unpublished observations), suggesting that 7E3 and LM 609 may bind to nearby sites on qP3. LM 609 alone had no effect on bead agglutination and the combination of 10E5 (anti-GPIIb/ IIIa) and LM 609 (anti-ct$,) was not more inhibitory than 10E5 alone. Thus, these data do not support the hypothesis that 7E3 is a more potent inhibitor than other antibodies to GPIIb/IIIa because it also reacts with a,#,.
PAC-1, which effectively inhibited the agglutination of GI-RGDF and G,-RGDF beads, had much less inhibitory activity than the other three antibodies when tested with the longer beads. With the G,-RGDF beads, for example, it produced only 8% inhibition at 30 minutes (Table 2 ). Thus, even though convincing evidence indicates that PAC-1 binds to the RGD-binding site:3 it was much less inhibitory than the other antibodies.
Trigramin at 3 to 4.5 pg/mL (-0.6 pmol/L), which is approximately twice the concentration reported to nearly saturate platelet GPIIb/IIIa receptors:' inhibited the agglutination with the shorter beads, but with the longer beads it inhibited only the early phase, such that at 30 minutes no inhibition was observed ( Table 2) . A similar inhibitory pattern was observed with the soluble RGDF peptide at -200 pg/mL (-400 pmol/L), consistent with data from Huang et a13' showing trigramin to be approximately 500fold more potent than RGDS peptides in inhibiting fibrinogen binding to platelets.
All of the antibodies against the other integrin receptors on platelets that may recognize RGD-containing sequences within their ligands (GoH3 [anti-Ic/IIa], MoAbl6 [anti-Ic*/IIa], and 6F1 [anti-Ia/IIa]) did not inhibit the bead agglutination ( Table 2 ; three separate experiments with each antibody). 6D1, directed against the nonintegrin receptor GPIb, also had no effect on the agglutination. Although these data suggest that the interactions between these receptors and the (G),-RGDF peptides do not contribute to the observed agglutination, this conclusion must be tempered because it is possible that these antibodies bind to the receptors in a way that inhibits the binding of the macromolecular ligands to the receptors without blocking access to the RGD binding site.
Incubation of citrated PRP with RGDS at concentrations up to 5 mmol/L did not inhibit the initial rate of 7E3 binding; in fact, there was a consistent increase in the rate (at 5 mmol/L a 66% increase in rate [n = 21, at 2.5 mmol/L a 63% increase in rate [n = 11, and at 0.5 to 1 mmol/L a 21% increase [n = 41). RGDS at similar concentrations had little or no effect on 10E5 binding, decreasing the rate by 5% in one experiment and increasing it by 2% and 24% in two other experiments. However, the longer RGD peptide [LGGAKQAGDV(R),RGDV] consistently inhibited the initial rate of binding of both 7E3 and 10E5. The effect on 7E3 was more pronounced, with increasing concentrations of the peptide showing increasing inhibition of the initial rate of 7E3 binding up to a maximum of -73% inhibition (n = 2) at 20 pmol/L. Concentrations of peptide much
Effect of RGDpeptides on 7E3 and lOE.5 binding.
higher than this (80 pmol/L to 1.67 mmol/L) failed to increase the inhibition significantly (76%; n = 8). Concentrations of the peptide up to 20 pmol/L caused progressively greater inhibition of the initial rate of 10E5 binding to platelets, plateauing at 43% inhibition; as with 7E3, further increases in peptide concentration failed to increase the inhibition (80 pmol/L to 1.67 mmol/L = 46%; n = 4).
DISCUSSION
The interaction of the RGD sequences contained in adhesive glycoproteins with receptors on the platelet surface is thought to be crucial to normal platelet function.3.10.1 1,12-14.17.l8,28 In the present study we have used immobilized RGD peptides containing variable numbers of glycine residues as structural probes of the platelet receptor(s) that mediate these interactions. Because these peptides differ from each other in length, flexibility, and the potential for assuming secondary structure, the differences in behavior we observed may result from any one or a combination of these differences. We found that the shortest immobilized peptide (G,-RGDF) reacted minimally with either unactivated or activated platelets in PRP, whereas the long peptides ( 2 G,-RGDF) interacted well with both unactivated and activated platelets, although the latter showed brisker interactions. In addition, the interactions with these longer peptides could induce the platelet release reaction, perhaps by causing receptor clustering. Inhibition of platelet activation with PGE, abolished the interaction of platelets with the beads containing the shorter peptides, but only partially inhibited the interaction of platelets with beads coated with the longer peptides. Peptides of intermediate size (G,-RGDF) showed the greatest sensitivity to the platelet's activation state, with virtually no interaction with platelets pretreated with PGE,, slow and incomplete interaction with native platelets, and brisk and extensive interaction with ADP-activated platelets.
In contrast to the enhanced ability of the longer immobilized peptides to interact with platelets, the longer peptides in solution were less potent than the shorter ones in inhibiting the interaction between platelets and fibrinogencoated beads. This finding indicates that the immobilized longer peptides do not show enhanced interaction with platelets as a result of an intrinsic affinity advantage conferred by the increased number of glycine residues; in fact, they had to overcome an intrinsic disadvantage with regard to affinity. Differences in peptide density on the beads also cannot account for the observed differences because the peptides were all immobilized at approximately the same density and dilutional studies indicated little effect of minor differences in peptide density. It is most likely, therefore, that the longer peptides were more effective because they could more easily gain access to the RGD binding sites in the receptors.
The minimal ability of the shortest peptides to interact with platelets under any conditions raises the possibility that the RGD binding sites may be recessed from the surface of the receptors by at least several angstroms. The gradient of increased interactions as the peptide length increased suggests that the RGD binding sites may be For personal use only. on October 3, 2017. by guest www.bloodjournal.org From arrayed at various depths, either because the receptors themselves are at variable distances from the platelet surface or because the RGD binding sites are variably recessed in the receptors. Because the increase in reactivity was most dramatic between the G,-RGDF and G,-RGDF beads, and because there was very little increase in platelet reactivity after the peptide length was increased beyond nine glycine residues, it is likely that most of the receptors lie within reach of the G,-RGDF and G,-RGDF peptides. To estimate the maximum lengths this range of peptides represents, we assume that the glycines adopt an extended conformation with 3.5 8, per glycine residue rather than an a-helical conformation in which case the glycines would be only 1.55 8, apart. We conclude, therefore, that the majority of RGD binding sites can be reached by peptides that extend out -11 to 32 8, from the surface of the bead.
Because not even minor increases in agglutination occurred with beads containing peptides longer than GI,-RGDF, we conclude that virtually all of the receptors can be reached by peptides that extend out -46 8, from the surface of the bead.
It is of interest to compare our results using the immobilized RGD peptides with integrin receptor structure deduced from electron microscopy of GPIIb/IIIa, the fibronectin receptor (VLA-5), and a chicken smooth muscle cell integrin(s).@-& The receptors contain three domains: a globular head (80 to 100 x -120 to 135 8,) from which extend two tails (20 x -155 to 200 8,) . The head region most likely contains the RGD binding site because it extends furthest from the membrane, and its -80 8, depth would be consistent with our data indicating that most of the RGD binding sites can be reached by peptides extending out -32 8, from the surface of the beads and that virtually all of them can be reached by peptides extending out -46 8, from the surface of the beads. Moreover, mass determinations led to the conclusion that the head is partially h o l l o~, @~~~ an interpretation that is also consistent with our inferences concerning the need for the RGD peptides to insinuate themselves into the RGD binding site after traversing a partially open labyrinth.
The increased response after ADP activation indicates that activation either causes the RGD binding sites to move closer to the platelet surface or increases the affinity of the receptor for the RGD peptides, perhaps by decreasing steric hindrance. The reduced agglutination response produced by PGE, suggests either that it causes the RGD binding sites to become more recessed or to have lower affinity, perhaps as a result of greater steric hindrance. However, even with PGE, pretreatment, the longer beads were able to produce substantial agglutination. This observation is consistent with our previous data using fibrinogencoated beads.33 One possible explanation is that even under maximal inhibition by an agent such as PGE, that increases platelet CAMP, the receptors are in a dynamic equilibrium between conformations that can interact with RGDcontaining ligands and others that cannot. The binding of a platelet via a receptor in the proper conformation to an RGD peptide on a bead would then allow the platelet to linger at the bead surface while additional receptors tran-siently adopt the proper conformation and bind other RGD peptides. Alternatively, or additionally, the length and flexibility of the longer peptides may allow them, with sufficient time, to insinuate themselves into the RGD binding sites of otherwise inaccessible receptors. There is also a possibility that interactions between platelets and the surface of the beads occur after the initial binding mediated via the RGD peptides. Finally, we cannot exclude the possibility that the increased efficacy of the longer RGD peptides is due to their ability to extend out from a complex geometry on the bead surface.
All of the MoAbs to GPIIb/IIIa that were tested can block platelet aggregation by ADP and dramatically inhibit fibrinogen binding to platelet^:^^^^^^^^^ and yet they showed considerable differences in their ability to inhibit the interactions with the immobilized RGD peptides. The most striking observation was the failure of PAC-1 to significantly inhibit the interaction between platelets and the longer immobilized RGD peptides even though there is compelling evidence that PAC-1 binds directly to the RGD binding site:, Technical considerations are unlikely to account for our inability to see inhibition with PAC-1 because we were careful to preincubate the platelets with ADP and PAC-1 before adding the beads. The most likely explanation for our finding is that the extraordinary density of immobilized peptides on the beads favors their interaction with the platelets, as discussed previously. Thus, even soluble RGDF and y-chain peptides had to be added in millimolar concentrations to significantly inhibit the interaction between platelets and the beads. For comparison, the RGDF peptide could significantly inhibit the interaction between platelets and the fibrinogen-coated beads even at concentrations that were 2 orders of magnitude lower. The highest concentration of PAC-1 that was tested was 60 pg/mL, which is only 7.5 x lo-* mol/L, and thus it is likely that the concentration used was inadequate. The ability of PAC-1 to inhibit agglutination induced by the shorter peptides would also be consistent with this interpretation. The failure of trigramin, an RGD-containing snake venom peptide:' to inhibit the agglutination at a dose that effectively inhibits platelet fibrinogen binding can also be explained on the basis of the concentration employed.
Of the remaining antibodies, 10E5 had the least effect on the agglutination. Because the small RGDS peptide did not inhibit 10E5 binding, it is unlikely that it binds at the RGD binding site. It is probable, therefore, that 10E5 binds to a region of GPIJb/IIIa that prevents access of the large ligands to the RGD binding site. The ability of the longer peptides to agglutinate the platelets preincubated with 10E5 probably results from their increased length and flexibility, allowing them to slowly circumvent the 10E5 block and reach the RGD binding site. A similar argument can explain the effect of A,&, but this antibody had a greater inhibitory effect on the RGD binding site.
7E3 was the most potent antibody, and because it reacts with both GPIIb/IIIa and the a,#, VnR, it is possible that its increased potency is a result of this cross-reactivity. However, we do not favor this explanation because antibody LM 609, which did not inhibit agglutination when used For personal use only. on October 3, 2017. by guest www.bloodjournal.org From alone or when added to 10E5, binds to a$, at a site that prevents 7E3 binding (unpublished observations). The inability of the RGDS peptide to inhibit the on-rate of 7E3 binding indicates that it does not bind at the RGD binding site. The ability of the longer RGD peptide to produce significant inhibition of 7E3 binding is consistent with 7E3 binding near to the RGD binding site, but potential allosteric changes induced by the binding of the RGD peptide make it impossible to be certain about the actual topographic relationships.
In conclusion, our data indicate that GPIIb/IIIa is the dominant RGD-binding receptor on the platelet surface and that most of the RGD binding sites can be reached by peptides that extend out -32 A from the surface of the beads. In addition, activation of the GPIIb/IIIa receptor decreases the depth of the RGD binding site and/or increases the affinity of the receptor for RGD peptides.
Moreover, MoAbs to GPIIb/IIIa that have similar effects on fibrinogen binding show disparate effects on the binding of the immobilized RGD peptides and these differences allow a functional assignment of effects on the RGD binding pocket. Finally, the identification of G3-RGDF as a peptide uniquely sensitive to the activation state of the GPIIb/IIIa receptor provides a tool for the potential design of platelet substitutes that will selectively interact with activated platelets:'
